04 2025.06
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 May 2025
29 2025.05
Next Day Disclosure Return
29 2025.05
COMPLETION OF PLACING OF H SHARES
27 2025.05
VOLUNTARY ANNOUNCEMENT - NATIONAL MEDICAL PRODUCTS ADMINISTRATION GRANTED MARKETING APPROVAL FOR TELITACICEPT FOR THE TREATMENT OF GENERALIZED MYASTHENIA GRAVIS IN CHINA
26 2025.05
TERMS OF REFERENCE OF THE REMUNERATION AND APPRAISAL COMMITTEE UNDER THE BOARD OF THE COMPANY
26 2025.05
TERMS OF REFERENCE OF THE NOMINATION COMMITTEE UNDER THE BOARD OF THE COMPANY
26 2025.05
TERMS OF REFERENCE OF THE AUDIT COMMITTEE UNDER THE BOARD OF THE COMPANY
26 2025.05
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
26 2025.05
CHANGE IN COMPOSITION OF THE NOMINATION COMMITTEE
26 2025.05
PROPOSED AMENDMENTS TO THE ARTICLES OF ASSOCIATION
27 2025.03
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2024
04 2024.12
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 November 2024
05 2024.11
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 October 2024
29 2024.10
2024 THIRD QUARTERLY REPORT
07 2024.10
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2024
25 2024.09
2024 Interim Report
05 2024.09
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 August 2024
16 2024.08
INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2024
06 2024.08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024
06 2024.08
(Revised) Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 June 2024
28 2024.06
ARTICLES OF ASSOCIATION
19 2022.04
Constitutional Documents ARTICLES OF ASSOCIATION
31 2022.03
Constitutional Documents - ARTICLES OF ASSOCIATION
06 2020.11
Constitutional Documents - ARTICLES OF ASSOCIATION
06 2020.11
SHAREHOLDERS’ COMMUNICATION POLICY
06 2020.11
PROCEDURES FOR SHAREHOLDERS TO NOMINATE AN INDIVIDUAL AS A DIRECTOR OR A SUPERVISOR OF THE COMPANY
06 2020.11
BOARD DIVERSITY POLICY